Gapping up
In reaction to strong earnings/guidance:
- SLP +9.7%, LEVI +7.4%, DAL +2.3%, GTBIF +2.2%, TSM +0.5%
Other news:
- JBLU +3.3% (reports March traffic +7.6% yr/yr; may announce trans-Atlantic routes; the company is hosting an event today - CNBC)
- AMGN +1.8% (Amgen and UCB confirm FDA approval for EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture)
- EXC +0.9% (upgraded to Neutral from Sell at Goldman)
- SNAP +0.6% (users could drop 2.8% yr/yr to 77.5 mln in FY19, according to eMarketer Research)
- LAZ +0.5% (reports preliminary assets under management)
Analyst comments:
- GH +5% (upgraded to Buy from Neutral at BofA/Merrill)
- FSLR +4.2% (target raised to $75 from $64 at Goldman and adds the name to the Conviction Buy List)
- KBH +1.9% (upgraded to Neutral from Underweight at JP Morgan)
- PHM +1.5% (upgraded to Neutral from Underweight at JP Morgan)
- GILD +1.4% (upgraded to Buy from Neutral at UBS)
- AMD +1.4% (target raised to $33 at Cowen)
- PAAS +0.9% (upgraded to Buy from Hold at Deutsche Bank)
- DIS +0.7% (upgraded to Outperform from Market Perform at BMO Capital Markets)